HK1087338A1 - USE OF AN AGENT THAT STABILIZES HIFa FOR PREPARATION OF MEDICAMENT FOR REGULATING FAT METABOLISM - Google Patents
USE OF AN AGENT THAT STABILIZES HIFa FOR PREPARATION OF MEDICAMENT FOR REGULATING FAT METABOLISMInfo
- Publication number
- HK1087338A1 HK1087338A1 HK06107698.4A HK06107698A HK1087338A1 HK 1087338 A1 HK1087338 A1 HK 1087338A1 HK 06107698 A HK06107698 A HK 06107698A HK 1087338 A1 HK1087338 A1 HK 1087338A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- medicament
- agent
- preparation
- fat metabolism
- regulating fat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43135102P | 2002-12-06 | 2002-12-06 | |
US47672603P | 2003-06-06 | 2003-06-06 | |
US47633103P | 2003-06-06 | 2003-06-06 | |
US10/729,167 US7618940B2 (en) | 2002-12-06 | 2003-12-04 | Fat regulation |
PCT/US2003/038690 WO2004052285A2 (en) | 2002-12-06 | 2003-12-05 | Fat regulation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1087338A1 true HK1087338A1 (en) | 2006-10-13 |
Family
ID=32512564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06107698.4A HK1087338A1 (en) | 2002-12-06 | 2006-07-10 | USE OF AN AGENT THAT STABILIZES HIFa FOR PREPARATION OF MEDICAMENT FOR REGULATING FAT METABOLISM |
Country Status (9)
Country | Link |
---|---|
US (2) | US7618940B2 (xx) |
EP (1) | EP1578431A4 (xx) |
JP (1) | JP2006514113A (xx) |
AU (1) | AU2003298926C1 (xx) |
CA (1) | CA2506159C (xx) |
HK (1) | HK1087338A1 (xx) |
IL (1) | IL168323A (xx) |
NO (1) | NO20053116L (xx) |
WO (1) | WO2004052285A2 (xx) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124582B2 (en) * | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
US7618940B2 (en) * | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
PL1644336T3 (pl) * | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
MX2008009581A (es) | 2006-01-27 | 2009-01-07 | Fibrogen Inc | Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih). |
WO2007101204A1 (en) * | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
US7745461B1 (en) | 2006-02-27 | 2010-06-29 | Alcon Research, Ltd. | Method of treating dry eye disorders |
MX2008012734A (es) * | 2006-04-04 | 2009-01-29 | Fibrogen Inc | Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif). |
US20080050740A1 (en) * | 2006-06-23 | 2008-02-28 | Cassidy Pamela M | Nutritional and Exercise Plan Based On A Person's Individual Genetic APO E Genotype |
EP3026044B8 (en) * | 2006-06-26 | 2018-12-19 | Akebia Therapeutics, Inc. | Prolyl hydroxylase inhibitors and methods of use |
WO2008076427A2 (en) * | 2006-12-18 | 2008-06-26 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
EP2097416B1 (en) * | 2006-12-18 | 2012-09-12 | Amgen, Inc | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
US7569726B2 (en) * | 2007-04-18 | 2009-08-04 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
JP2010524942A (ja) * | 2007-04-18 | 2010-07-22 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン |
AU2008248165B2 (en) * | 2007-05-04 | 2011-12-08 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
EP2150251B9 (en) * | 2007-05-04 | 2013-02-27 | Amgen, Inc | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
EP2227475B1 (en) * | 2007-12-03 | 2014-02-19 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
WO2009089547A1 (en) * | 2008-01-11 | 2009-07-16 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
CN102076680B (zh) | 2008-04-28 | 2016-03-02 | 詹森药业有限公司 | 作为脯氨酰羟化酶抑制剂的苯并咪唑 |
EP2334682B1 (en) * | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
US8927591B2 (en) | 2008-11-14 | 2015-01-06 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
US8937078B2 (en) | 2009-02-10 | 2015-01-20 | Janssen Pharmaceutica Nv | Quinazolinones as prolyl hydroxylase inhibitors |
CN103068821B (zh) | 2010-08-13 | 2015-02-25 | 詹森药业有限公司 | 作为脯氨酰羟化酶抑制剂的4-氨基喹唑啉-2-基-1-吡唑-4-羧酸化合物 |
US8921389B2 (en) | 2011-02-02 | 2014-12-30 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase |
JPWO2012105630A1 (ja) * | 2011-02-03 | 2014-07-03 | 国立大学法人広島大学 | 脂質代謝関連疾患の検査方法、ならびに脂質代謝関連疾患の予防および/または治療剤の評価方法 |
GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
NO2686520T3 (xx) | 2011-06-06 | 2018-03-17 | ||
WO2012170439A1 (en) | 2011-06-06 | 2012-12-13 | The Ohio State University | Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
HUE052128T2 (hu) | 2011-10-25 | 2021-04-28 | Janssen Pharmaceutica Nv | Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására |
US9409892B2 (en) | 2012-03-09 | 2016-08-09 | Fibrogen, Inc. | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors |
CN104427980A (zh) * | 2012-03-09 | 2015-03-18 | 菲布罗根有限公司 | 高胆固醇的治疗 |
ES2631655T3 (es) * | 2012-07-16 | 2017-09-01 | Fibrogen, Inc. | Procedimiento para fabricar compuestos de isoquinolina |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
SI3470397T1 (sl) | 2012-07-16 | 2022-07-29 | Fibrogen, Inc. | Kristalinične oblike zaviralca prolil hidroksilaze |
KR102233081B1 (ko) | 2013-01-24 | 2021-03-29 | 피브로겐, 인크. | 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태 |
DK3003284T3 (da) * | 2013-06-06 | 2020-03-30 | Fibrogen Inc | Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor |
CN114404414A (zh) | 2013-06-13 | 2022-04-29 | 阿克比治疗有限公司 | 用于治疗贫血症的组合物和方法 |
AR099354A1 (es) | 2013-11-15 | 2016-07-20 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos |
WO2016118858A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
BR112017021097B1 (pt) | 2015-04-01 | 2024-01-02 | Akebia Therapeutics, Inc | Formulação de dosagem oral e seu uso |
WO2016164593A1 (en) * | 2015-04-07 | 2016-10-13 | President And Fellows Of Harvard College | Compositions and methods for modulating hydroxylation of acc2 by phd3 |
CN109180580B (zh) | 2016-02-28 | 2021-01-12 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的杂芳基化合物及包含该化合物的组合物及其用途 |
AU2017406103B2 (en) * | 2017-03-29 | 2023-12-14 | Emerald Health Pharmaceuticals, Inc. | Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity |
TWI822776B (zh) | 2018-05-09 | 2023-11-21 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
CN113164334A (zh) * | 2018-10-12 | 2021-07-23 | 米拉基创新智库有限责任公司 | 用于减脂的低温溶液 |
US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE878480C (de) * | 1951-05-16 | 1953-06-05 | Richard Abr Herder Fa | Drehmomentschluessel |
TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
ES2101420T3 (es) | 1993-11-02 | 1997-07-01 | Hoechst Ag | Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
GB9402857D0 (en) | 1994-02-15 | 1994-04-06 | Isis Innovation | Targeting gene therapy |
DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
BR9710272A (pt) * | 1996-07-12 | 1999-08-10 | Smithkline Beecham Plc | Novo tratamento de resisténcia a leptina |
DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP0878480A1 (en) * | 1997-05-14 | 1998-11-18 | H.W. Prof. Dr. Müller | A method for the improvement of neuronal regeneration |
DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
US5916898A (en) * | 1997-10-24 | 1999-06-29 | Zeneca Limited | Phenanthroline derivatives |
WO1999021860A1 (en) | 1997-10-24 | 1999-05-06 | Fibrogen, Inc. | Phenanthroline derivatives |
US6200974B1 (en) | 1997-10-24 | 2001-03-13 | Zeneca Limited | Phenanthroline derivatives |
NZ504847A (en) | 1997-12-04 | 2003-02-28 | Genzyme Corp | Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use |
US6124131A (en) | 1998-08-25 | 2000-09-26 | The Johns Hopkins University School Of Medicine | Mutant hypoxia inducible factor-1 HIF-1 |
WO2002074981A2 (en) | 2001-03-21 | 2002-09-26 | Isis Innovation Ltd. | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
US20030008838A1 (en) * | 2001-04-03 | 2003-01-09 | Havel Peter J. | Method of increasing endogenous leptin production |
WO2003045440A1 (en) | 2001-11-28 | 2003-06-05 | Angiogenetics Sweden Ab | Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein |
US20030176317A1 (en) | 2001-12-06 | 2003-09-18 | Volkmar Guenzler-Pukall | Stabilization of hypoxia inducible factor (HIF) alpha |
GB0206711D0 (en) | 2002-03-21 | 2002-05-01 | Isis Innovation | HIF Inhibitor |
JP2004083570A (ja) * | 2002-06-25 | 2004-03-18 | Sankyo Co Ltd | 低酸素応答誘導剤およびその製法 |
US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
-
2003
- 2003-12-04 US US10/729,167 patent/US7618940B2/en active Active
- 2003-12-05 WO PCT/US2003/038690 patent/WO2004052285A2/en active Application Filing
- 2003-12-05 EP EP03796688A patent/EP1578431A4/en not_active Withdrawn
- 2003-12-05 AU AU2003298926A patent/AU2003298926C1/en not_active Ceased
- 2003-12-05 CA CA2506159A patent/CA2506159C/en not_active Expired - Fee Related
- 2003-12-05 JP JP2005508474A patent/JP2006514113A/ja active Pending
-
2005
- 2005-05-02 IL IL168323A patent/IL168323A/en active IP Right Grant
- 2005-06-24 NO NO20053116A patent/NO20053116L/no not_active Application Discontinuation
-
2006
- 2006-07-10 HK HK06107698.4A patent/HK1087338A1/xx not_active IP Right Cessation
-
2009
- 2009-10-19 US US12/589,229 patent/US8202834B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2003298926C1 (en) | 2010-02-04 |
US7618940B2 (en) | 2009-11-17 |
US8202834B2 (en) | 2012-06-19 |
AU2003298926A1 (en) | 2004-06-30 |
CA2506159C (en) | 2011-05-24 |
JP2006514113A (ja) | 2006-04-27 |
AU2003298926B2 (en) | 2009-09-03 |
WO2004052285A2 (en) | 2004-06-24 |
US20040235082A1 (en) | 2004-11-25 |
EP1578431A4 (en) | 2008-04-23 |
NO20053116D0 (no) | 2005-06-24 |
CA2506159A1 (en) | 2004-06-24 |
NO20053116L (no) | 2005-09-05 |
IL168323A (en) | 2011-07-31 |
EP1578431A2 (en) | 2005-09-28 |
WO2004052285A3 (en) | 2004-09-02 |
US20100168152A1 (en) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1087338A1 (en) | USE OF AN AGENT THAT STABILIZES HIFa FOR PREPARATION OF MEDICAMENT FOR REGULATING FAT METABOLISM | |
HK1089107A1 (en) | Delivery of therapeutic compounds to the brain and other tissues | |
EP1673104A4 (en) | DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE | |
EP1638605A4 (en) | DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE | |
EP1727530A4 (en) | TOPICAL FORMULATIONS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | |
IL175529A0 (en) | Methods and compositions for the treatment of metabolic disorders | |
IL169338A0 (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
IL169332A0 (en) | Compounds for the treatment of metabolic disorders | |
ZA200707934B (en) | Thereapeutic formulations for the treatment of beta-amyloid related diseases | |
HK1073997A1 (en) | Administration of agents for the treatment of inflammation | |
IL165820A0 (en) | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | |
IL165397A0 (en) | Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders | |
EP1372726A4 (en) | METHOD FOR REDUCING FAT BY ADMINISTRATING ADIPONECTIN | |
AU2003228819A8 (en) | Combinations for the treatment of inflammatory skin disorders | |
AU2003286728A8 (en) | Compounds for the treatment of metabolic disorders | |
PL1740204T3 (pl) | Lecznicze zastosowanie alfa-mannozydazy | |
EP1636160A4 (en) | NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLISM AND SKIN DISEASES | |
EP1539100A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS | |
IL172101A0 (en) | Use of indazole derivatives for the treatment of neuropathic pain | |
EP1677745A4 (en) | NITRON COMPOUND PRODRUGS AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF HUMAN DISEASES | |
AU2003266210A8 (en) | Use of mas-compounds for treating diseases associated with lipid metabolism | |
GB0304871D0 (en) | Formulation for treatment of paralizing pain stiffness | |
AU2003213349A1 (en) | Therapeutic agent for pain | |
AU2003224561A1 (en) | Use of dhea for treatment of female hypopituitarism | |
AU2003279461A8 (en) | Disorders of lipid metabolism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20131205 |